Across TCGA pan-cancer cohorts, NUDT16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NUDT16 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NUDT16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NUDT16 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NUDT16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.512	0.285	<.001	56	view →
CCRCC	DFS	Median	All	0.973	0.480	.001	35	view →
LUAD	OS	Median	All	0.905	0.761	.007	11	view →
HNSC	OS	Median	IV	0.961	0.741	.005	6	view →
UCEC	OS	Quartile	II,III,IV	0.525	1.000	.043	4	view →
GBM	OS	Quartile	All	0.779	0.918	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: NUDT16 tumor-vs-normal RNA expression · all NUDT16 data types